Spero Therapeutics (SPRO) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to 0.49.
- Spero Therapeutics' Equity Ratio rose 91.42% to 0.49 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.49, marking a year-over-year increase of 91.42%. This contributed to the annual value of 0.42 for FY2024, which is 2880.75% down from last year.
- Per Spero Therapeutics' latest filing, its Equity Ratio stood at 0.49 for Q3 2025, which was up 91.42% from 0.53 recorded in Q2 2025.
- Spero Therapeutics' Equity Ratio's 5-year high stood at 0.83 during Q1 2021, with a 5-year trough of 0.42 in Q4 2024.
- Over the past 5 years, Spero Therapeutics' median Equity Ratio value was 0.54 (recorded in 2024), while the average stood at 0.56.
- As far as peak fluctuations go, Spero Therapeutics' Equity Ratio plummeted by 4829.52% in 2022, and later surged by 3448.09% in 2023.
- Over the past 5 years, Spero Therapeutics' Equity Ratio (Quarter) stood at 0.52 in 2021, then grew by 17.89% to 0.61 in 2022, then fell by 3.68% to 0.59 in 2023, then fell by 28.81% to 0.42 in 2024, then increased by 17.22% to 0.49 in 2025.
- Its last three reported values are 0.49 in Q3 2025, 0.53 for Q2 2025, and 0.44 during Q1 2025.